CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations

Melanoma remains a critical public health problem worldwide. Patients with stage IV disease have very poor prognosis and their 1-year survival rate is only 25%. Until recently, systemic treatments with a positive impact on overall survival (OS) had remained elusive. In recent years, the United State...

Descripción completa

Detalles Bibliográficos
Autor principal: Camacho, Luis H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2015
Materias:
Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4430259/
https://www.ncbi.nlm.nih.gov/pubmed/25619164
http://dx.doi.org/10.1002/cam4.371

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4430259/
https://www.ncbi.nlm.nih.gov/pubmed/25619164
http://dx.doi.org/10.1002/cam4.371

Ejemplares similares